The global neuroendocrine tumor treatment market size is calculated at USD 2.88 billion in 2025 and is forecasted to reach around USD 4.89 billion by 2034, accelerating at a notable CAGR of 6.09% from 2025 to 2034. The North America market size surpassed USD 1.14 billion in 2024 and is expanding at a CAGR of 6.19% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neuroendocrine Tumor Treatment Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neuroendocrine Tumor Treatment Market, by Type
8.1.1. Meningiomas
8.1.1.1. Market Revenue and Forecast
8.1.2. Adrenal Cancer
8.1.2.1. Market Revenue and Forecast
8.1.3. Carcinoid Tumors
8.1.3.1. Market Revenue and Forecast
8.1.4. Paraganglioma
8.1.4.1. Market Revenue and Forecast
8.1.5. Pheochromocytoma
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Neuroendocrine Tumor Treatment Market, by Product
9.1.1. Somatostatin Analogs (SSAs)
9.1.1.1. Market Revenue and Forecast
9.1.2. Targeted Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Neuroendocrine Tumor Treatment Market, by Site
10.1.1. Lung
10.1.1.1. Market Revenue and Forecast
10.1.2. Pancreas
10.1.2.1. Market Revenue and Forecast
10.1.3. Colon
10.1.3.1. Market Revenue and Forecast
10.1.4. Small Intestine
10.1.4.1. Market Revenue and Forecast
10.1.5. Rectum
10.1.5.1. Market Revenue and Forecast
10.1.6. Stomach
10.1.6.1. Market Revenue and Forecast
10.1.7. Others
10.1.7.1. Market Revenue and Forecast
11.1. Neuroendocrine Tumor Treatment Market, by End-use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type
12.1.2. Market Revenue and Forecast, by Product
12.1.3. Market Revenue and Forecast, by Site
12.1.4. Market Revenue and Forecast, by End-use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type
12.1.5.2. Market Revenue and Forecast, by Product
12.1.5.3. Market Revenue and Forecast, by Site
12.1.5.4. Market Revenue and Forecast, by End-use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type
12.1.6.2. Market Revenue and Forecast, by Product
12.1.6.3. Market Revenue and Forecast, by Site
12.1.6.4. Market Revenue and Forecast, by End-use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type
12.2.2. Market Revenue and Forecast, by Product
12.2.3. Market Revenue and Forecast, by Site
12.2.4. Market Revenue and Forecast, by End-use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type
12.2.5.2. Market Revenue and Forecast, by Product
12.2.5.3. Market Revenue and Forecast, by Site
12.2.5.4. Market Revenue and Forecast, by End-use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type
12.2.6.2. Market Revenue and Forecast, by Product
12.2.6.3. Market Revenue and Forecast, by Site
12.2.6.4. Market Revenue and Forecast, by End-use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type
12.2.7.2. Market Revenue and Forecast, by Product
12.2.7.3. Market Revenue and Forecast, by Site
12.2.7.4. Market Revenue and Forecast, by End-use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type
12.2.8.2. Market Revenue and Forecast, by Product
12.2.8.3. Market Revenue and Forecast, by Site
12.2.8.4. Market Revenue and Forecast, by End-use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type
12.3.2. Market Revenue and Forecast, by Product
12.3.3. Market Revenue and Forecast, by Site
12.3.4. Market Revenue and Forecast, by End-use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type
12.3.5.2. Market Revenue and Forecast, by Product
12.3.5.3. Market Revenue and Forecast, by Site
12.3.5.4. Market Revenue and Forecast, by End-use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type
12.3.6.2. Market Revenue and Forecast, by Product
12.3.6.3. Market Revenue and Forecast, by Site
12.3.6.4. Market Revenue and Forecast, by End-use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type
12.3.7.2. Market Revenue and Forecast, by Product
12.3.7.3. Market Revenue and Forecast, by Site
12.3.7.4. Market Revenue and Forecast, by End-use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type
12.3.8.2. Market Revenue and Forecast, by Product
12.3.8.3. Market Revenue and Forecast, by Site
12.3.8.4. Market Revenue and Forecast, by End-use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type
12.4.2. Market Revenue and Forecast, by Product
12.4.3. Market Revenue and Forecast, by Site
12.4.4. Market Revenue and Forecast, by End-use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type
12.4.5.2. Market Revenue and Forecast, by Product
12.4.5.3. Market Revenue and Forecast, by Site
12.4.5.4. Market Revenue and Forecast, by End-use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type
12.4.6.2. Market Revenue and Forecast, by Product
12.4.6.3. Market Revenue and Forecast, by Site
12.4.6.4. Market Revenue and Forecast, by End-use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type
12.4.7.2. Market Revenue and Forecast, by Product
12.4.7.3. Market Revenue and Forecast, by Site
12.4.7.4. Market Revenue and Forecast, by End-use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type
12.4.8.2. Market Revenue and Forecast, by Product
12.4.8.3. Market Revenue and Forecast, by Site
12.4.8.4. Market Revenue and Forecast, by End-use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type
12.5.2. Market Revenue and Forecast, by Product
12.5.3. Market Revenue and Forecast, by Site
12.5.4. Market Revenue and Forecast, by End-use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type
12.5.5.2. Market Revenue and Forecast, by Product
12.5.5.3. Market Revenue and Forecast, by Site
12.5.5.4. Market Revenue and Forecast, by End-use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type
12.5.6.2. Market Revenue and Forecast, by Product
12.5.6.3. Market Revenue and Forecast, by Site
12.5.6.4. Market Revenue and Forecast, by End-use
13.1. Novartis
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Ipsen Pharma
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Chimeric Therapeutics
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bristol-Myers Squibb Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Hutchison MediPharma Limited.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AVEO Pharmaceuticals, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bayer
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Boehringer Ingelheim International GmbH
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Sumitomo Dainippon Pharma
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample